Annexon, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ANNX in the last 30 days.
See all $ANNX insider activity →Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. Key updates include ARCHER II trial progress in geographic atrophy and plans for a BLA submission for tanruprubart in Q4 2026. Management projects funding into 2028.
Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. ARCHER II trial for geographic atrophy enrolled 659 patients, exceeding targets. Tanruprubart for Guillain-Barré syndrome (GBS) is on track for BLA submission in Q4 2026, with positive FORWARD study data. Operations are funded into 2028.
Annexon, Inc. reported Q2 2026 updates on tanruprubart and vonaprument. For ARCHER II in geographic atrophy, management added a month 24 primary endpoint alongside month 15, citing over-enrollment and retention. In FORWARD for GBS, management said rapid benefit was reproduced in Western cohorts. Annexon plans FDA BLA submission for GBS in Q4 2024 and has a $200M credit facility extending runway to 2028.
Over the past 7 days, alphai's AI scored 1 news story mentioning ANNX (Annexon, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent ANNX coverage spans earnings, technology and market movers.
The earnings release shows increased R&D spend and a sizable new credit facility, indicating continued cash runway but higher losses, while positive trial enrollment data may support future upside.
Earnings beat expectations on cash runway but increased loss may pressure near-term price.
The endpoint design change can materially affect perceived Phase 3 risk and the probability-weighted path to FDA submission and labeling.
Dual primary endpoint adoption can alter perceived probability of regulatory success and the shape of the risk-reward into upcoming trial readouts and filings.
The call reinforces vonaprument’s clinical narrative (rapid functional gains, vision-preservation goal) and updates ARCHER II readout timing, which can shift biotech risk pricing.
alphai scores every news story that mentions ANNX with an AI model for sentiment and relevance, and aggregates insider trades from Annexon, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. Key updates include ARCHER II trial progress in geographic atrophy and plans for a BLA submission for tanruprubart in Q4 2026. Management projects funding into 2028.
3 min readAnnexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. ARCHER II trial for geographic atrophy enrolled 659 patients, exceeding targets. Tanruprubart for Guillain-Barré syndrome (GBS) is on track for BLA submission in Q4 2026, with positive FORWARD study data. Operations are funded into 2028.
3 min readAnnexon, Inc. reported Q2 2026 updates on tanruprubart and vonaprument. For ARCHER II in geographic atrophy, management added a month 24 primary endpoint alongside month 15, citing over-enrollment and retention. In FORWARD for GBS, management said rapid benefit was reproduced in Western cohorts. Annexon plans FDA BLA submission for GBS in Q4 2024 and has a $200M credit facility extending runway to 2028.
7 min readSimply Wall St reports Annexon (ANNX) shares fell about 6.1% after ARCHER II trial updates for vonaprument, including a shift to dual primary endpoints covering 15 and 24 months for geographic atrophy. The article cites Q2 2026 net loss of $55.35 million and says non-dilutive financing up to $200 million extends its cash runway into 2028.
6 min readAnnexon (NASDAQ:ANNX) reported Q2 call highlights for its complement-targeted therapy tanruprubart in Guillain-Barre syndrome, saying patients showed rapid functional gains and ventilator weaning within days, with adverse events linked to GBS complications. The company also added a 24-month endpoint to ARCHER II for vonaprument, with 15-month review expected in Q4 2026 and results in 2027.
5 min readAnnexon Biosciences (ANNX) reported Q2 2026 results and clinical updates. It said Phase 3 FORWARD tanruprubart in Guillain-Barre has treated the first 10 U.S. and European patients and expects a Q4 2026 BLA filing. For vonaprument in geographic atrophy, ARCHER II remains on track with Month 15 data in Q4 2026 and final completion in Q3 2027. Q2 R&D was $46.6M, net loss $55.3M. Cash was $209.2M. A $200M credit facility was arranged with $50M drawn.
6 min readU.S. stock futures edged higher ahead of CPI, with investors watching for signals on the Fed’s rate path. In premarket movers, Super Micro Computer rose over 9% on full-year guidance above expectations. H&R Block gained 13.9% after Q4 adjusted EPS of $2.38 vs $2.31 consensus, revenue $3.95B, and FY27 EPS outlook $6.04-$6.24. Other movers included Owlet, Valens Semiconductor, and Riskified.
4 min readAnnexon, Inc. (Nasdaq: ANNX) reported Q2 2026 results and clinical updates. It said tanruprubart GBS data support a Q4 2026 BLA submission, and vonaprument GA Phase 3 ARCHER II is on track with a Month 15 endpoint in Q4 2026 and Month 24 in Q3 2027. Cash was $209.2M at June 30, 2026; net loss was $55.3M. It also secured a $200M credit facility.
7 min readAnnexon, Inc. (Nasdaq: ANNX) said it added a Month 24 dual primary endpoint to its Phase 3 ARCHER II trial of vonaprument for geographic atrophy in dry AMD, alongside the existing Month 15 endpoint. It also launched an open-label extension for long-term safety and benefit. Month 15 DMC assessment is expected in Q4 2026, with Month 24 results in Q3 2027.
3 min readAnnexon, Inc. (ANNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-W
5 min read
